Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

LONDON/COPENHAGEN (Reuters) - Novo Nordisk emissions grew 23% in 2024 ... "Sounds like a fairy tale," said Sasja Beslik, ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

“Let’s not forget that it is still a duopoly industry,” said Tom O’Hara, a European equities portfolio manager at Janus Henderson Investors, referring to Novo Nordisk and Eli Lilly. “Yes there will be ...

Read Less Project management software makes it easy to plan projects, allocate tasks and keep teams organised so that deadlines and goals are met. Our research shows that ClickUp is the clear ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), has been censured by the UK’s Prescription Medicines Code of Practice ...

Currently, central government employees get salaries based on the recommendations of the 7th Pay Commission, whose term will end on December 31, 2025. The central government has approved the ...

In June 2021, Novo Nordisk won FDA approval for Ozempic's sibling, Wegovy, both of which share the same active ingredient (semaglutide), as a treatment for chronic weight management. The rest ...